CN101259235A - Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof - Google Patents
Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof Download PDFInfo
- Publication number
- CN101259235A CN101259235A CNA2008100882410A CN200810088241A CN101259235A CN 101259235 A CN101259235 A CN 101259235A CN A2008100882410 A CNA2008100882410 A CN A2008100882410A CN 200810088241 A CN200810088241 A CN 200810088241A CN 101259235 A CN101259235 A CN 101259235A
- Authority
- CN
- China
- Prior art keywords
- gram
- radix
- medicine
- angelicae sinensis
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides a compound Chinese medicine preparation for clearing heat and toxic substance and resisting tumors and a preparation method thereof. The preparation is extracted from the following Chinese medicines: 8 to 20g of peony tree root bark, 20 to 80g of oldenlandia diffusa, 5 to 20g of angelica, 3 to 18g of rhizoma sparganii, 5 to 30g of milk veteh, 8 to 25g of dyer woad leaf, 8 to 30g of glehnia root, 5 to 25g of purple gromwell root, 10 to 40g of barbed skullcap fruit, 5 to 25g of boxthorn root bark and 10 to 100g of Rumex japonicus (an ingredient added to enhance the efficacy of a dose of medicine). The medicine has the good effects of bacteria repellency and disinfection, immunity enhancement, leukemia cell resistance, tumor cell transfer inhibition, medullary blood forming function and hematoblastic growth promotion. The prescription is particularly developed for curing leukemia and has no toxic side effect. In addition, all the raw materials are natural herbs, so the cost is low.
Description
The present invention relates to a kind of oral drugs, is a kind of heat-clearing and toxic substances removing that has specifically, benefiting QI and nourishing blood, the silt mass-dissipating efficacy of dispelling, the Chinese traditional compound medicine of the acute myeloblastic leukemia in the treatment acute leukemia, and the method for producing this medicine.
The leukemic drug main of treatment on the market is wanted mitigate the disease now, even chemotherapy also can cause the cell and the hemopoietic function complete failure of health, if the later stage bone marrow has the possibility of inefficacy equally,, also there is repulsion little certainly even success also exclusive problem can occur.So need the leukemic Chinese medicine of a kind of safe and effective healing extremely urgent.
Purpose of the present invention provides a kind of Chinese traditional compound medicine and production method thereof for the treatment of acute myeloblastic leukemia, and its set of guidelines designs acute myeloblastic leukemia, and to this sick good effect, and production cost is low.
Chinese traditional compound medicine of the present invention comprises gained from following prescription Chinese medicine:
Cortex Moutan 8-20 gram; Herba Hedyotidis Diffusae 20-80 gram; Radix Angelicae Sinensis 5-20 gram; Rhizoma sparganic 3-18 gram; Radix Astragali 5-30 gram; Folium Isatidis 8-25 gram; Radix Glehniae 8-30 gram; Radix Arnebiae (Radix Lithospermi) 5-25 gram; Herba Scutellariae Barbatae 10-40 gram; Cortex Lycii 5-25 gram; YANGTI TANG 10-100 restrains (extra conductant ingredient).
The composition that this discovery Chinese traditional compound medicine is further optimized is to comprise gained from following prescription Chinese medicine:
Cortex Moutan 5.5-10.5 gram; Herba Hedyotidis Diffusae 10-30 gram; Radix Angelicae Sinensis 7.5-10 gram; Rhizoma sparganic 2.5-5.5 gram; Radix Astragali 6.5-8.5 gram; Folium Isatidis 5.5-10 gram; Radix Glehniae 2.5-8.5 gram; Radix Arnebiae (Radix Lithospermi) 2.5-8 gram; Radix Paeoniae Rubra 6.5-12 gram; Herba Scutellariae Barbatae 4.5-10 gram; Cortex Lycii 7.5-12 gram; YANGTI TANG 15-35 restrains (extra conductant ingredient).
The production method of Chinese traditional compound medicine of the present invention: with Cortex Moutan, Herba Hedyotidis Diffusae, Radix Angelicae Sinensis, rhizoma sparganic, the Radix Astragali, Folium Isatidis, Radix Glehniae, Radix Arnebiae (Radix Lithospermi), Herba Scutellariae Barbatae, Cortex Lycii, soak the back and decoct three times, collecting decoction, filtration, filtrate decompression concentrates, leave standstill after-filtration and remove precipitation, filtrate recovery is condensed into thick paste, and cold drying pulverize, tablet or capsule are random.
Cortex Moutan antipyretic-antalgic in the prescription of the present invention, antitumor suppresses complement and generates; Herba Hedyotidis Diffusae is an anti-inflammation, increases immunologic function; Radix Angelicae Sinensis is an antithrombotic, increases the ability of inducement interferon; Rhizoma sparganic microcirculation improvement and hemorheological property increase vascular permeability, promote tissue repair and regeneration; The Radix Astragali is that enhancing antibody and immunoglobulin are synthetic; Folium Isatidis is analgesic.Toxic action in the significant antibacterium; Radix Glehniae is to regulate immunologic balance; Radix Arnebiae (Radix Lithospermi) leukemia cell; Radix Paeoniae Rubra suppresses the transfer of tumor cell; The Herba Scutellariae Barbatae heat-clearing and toxic substances removing; The Cortex Lycii detumescence of drawing out pus by applying a plaster to the affected part; YANGTI TANG has the increase capillary resistance, shortens clotting time, and can promote the hemopoietic function and the hematoblastic growth of bone marrow; 12 flavor Chinese medicines have effects such as heat-clearing and toxic substances removing, anticancer increase immunity of organisms through scientific composition.Clinical treatment acute myeloblastic leukemia total effective rate 90%, cure rate reaches 65%, and the treatment works well, and certain market prospect is arranged, and the clinical experiment result is as follows:
Patient's situation: 20,5 years old-20 years old, wherein light-duty 13 examples, condition of illness is not liked activity, loss of appetite; Medium-sized 5 examples, hemoglobin reduction causes anemia; Heavy 2 examples, hepatosplenomegaly, lymphadenectasis, body temperature often is higher than 38.5 degrees centigrade.
Therapeutic scheme: oral capsule of the present invention, 2 of per kilogram of body weight clothes, every day 3 times, 7 days each courses of treatment.(annotating YANGTI TANG) as extra conductant ingredient
Criterion of therapeutical effect:
Recovery from illness: took medicine 14 days-35 days, temperature recovery is normal, and it is normal that abnormal index recovers.
Produce effects: took medicine 14 days-35 days, temperature recovery is normal, and abnormal index makes moderate progress.
Invalid: all symptoms do not have improvement.
The invention has the beneficial effects as follows that its prescription system is in particular the treatment acute myeloblastic leukemia and develops,, have no side effect therefore to leukemic good effect; In addition since raw materials used be natural plants only, so cost is low.
Embodiment 1:
Get Cortex Moutan 100 grams; Herba Hedyotidis Diffusae 260 grams; Radix Angelicae Sinensis 80 grams; Rhizoma sparganic 150 grams; The Radix Astragali 120 grams; Folium Isatidis 88 grams; Radix Glehniae 105 grams; Radix Arnebiae (Radix Lithospermi) 200 grams; Herba Scutellariae Barbatae 80 grams; Cortex Lycii 65 grams are soaked the back and are decocted three times, filtration, and filtrate decompression concentrates, and leaves standstill after-filtration and removes precipitation, and filtrate recovery is condensed into thick paste, and cold drying pulverize, adding appropriate amount of auxiliary materials are made granule, divide encapsulated.
Embodiment 2:
Get Cortex Moutan 200 grams; Herba Hedyotidis Diffusae 530 grams; Radix Angelicae Sinensis 270 grams; Rhizoma sparganic 310 grams; The Radix Astragali 205 grams; Folium Isatidis 185 grams; Radix Glehniae 230 grams; Radix Arnebiae (Radix Lithospermi) 345 grams; Herba Scutellariae Barbatae 115 grams; Cortex Lycii 175 grams are soaked the back and are decocted three times, filtration, and filtrate decompression concentrates, and leaves standstill after-filtration and removes precipitation, and filtrate recovery is condensed into thick paste, and cold drying pulverize, adding appropriate amount of auxiliary materials tabletting are made tablet.
Above embodiment is only for the present invention is further illustrated, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (4)
1, a kind of Chinese traditional compound medicine for the treatment of acute myeloblastic leukemia is characterized in that obtaining in the Chinese medicine by following prescription: Cortex Moutan 8-20 gram; Herba Hedyotidis Diffusae 20-80 gram; Radix Angelicae Sinensis 5-20 gram; Rhizoma sparganic 3-18 gram; Radix Astragali 5-30 gram; Folium Isatidis 8-25 gram; Radix Glehniae 8-30 gram; Radix Arnebiae (Radix Lithospermi) 5-25 gram; Herba Scutellariae Barbatae 10-40 gram; Cortex Lycii 5-25 gram; YANGTI TANG 10-100 restrains (extra conductant ingredient).
2, as the said Chinese traditional compound medicine of claim, it is characterized in that obtaining in the Chinese medicine by following prescription: Cortex Moutan 5.5-10.5 gram; Herba Hedyotidis Diffusae 10-30 gram; Radix Angelicae Sinensis 7.5-10 gram; Rhizoma sparganic 2.5-5.5 gram; Radix Astragali 65-8.5 gram; Folium Isatidis 5.5-10 gram; Radix Glehniae 2.5-8.5 gram; Radix Arnebiae (Radix Lithospermi) 2.5-8 gram; Radix Paeoniae Rubra 65-12 gram; Herba Scutellariae Barbatae 45-10 gram; Cortex Lycii 75-12 gram; YANGTI TANG 15-35 restrains (extra conductant ingredient).
3, as the production method of the arbitrary said Chinese traditional compound medicine of claim 1-2, it is characterized in that Cortex Moutan, Herba Hedyotidis Diffusae, Radix Angelicae Sinensis, rhizoma sparganic, the Radix Astragali, Folium Isatidis, Radix Glehniae, Radix Arnebiae (Radix Lithospermi), Herba Scutellariae Barbatae, Cortex Lycii, soak back decoction three times, collecting decoction, filtration, filtrate decompression concentrates, leave standstill after-filtration and remove precipitation, filtrate recovery is condensed into thick paste, cold drying pulverize.
4,, it is characterized in that Cortex Moutan, Herba Hedyotidis Diffusae, Radix Angelicae Sinensis, rhizoma sparganic, the Radix Astragali, Folium Isatidis, Radix Glehniae, Radix Arnebiae (Radix Lithospermi), Herba Scutellariae Barbatae, Cortex Lycii, soak back decoction three times as the production method of the said Chinese traditional compound medicine of claim 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100882410A CN101259235B (en) | 2008-03-25 | 2008-03-25 | Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100882410A CN101259235B (en) | 2008-03-25 | 2008-03-25 | Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101259235A true CN101259235A (en) | 2008-09-10 |
| CN101259235B CN101259235B (en) | 2011-01-26 |
Family
ID=39960067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100882410A Expired - Fee Related CN101259235B (en) | 2008-03-25 | 2008-03-25 | Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101259235B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362886A (en) * | 2015-12-02 | 2016-03-02 | 钊桂英 | Preparation for treating acute leukemia and preparation method |
| CN107007722A (en) * | 2017-03-31 | 2017-08-04 | 天津市善济宏兴科技发展有限公司 | For treating the leukemogenic compound Chinese medicinal preparation of interior hot stasis institute and preparation method |
-
2008
- 2008-03-25 CN CN2008100882410A patent/CN101259235B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105362886A (en) * | 2015-12-02 | 2016-03-02 | 钊桂英 | Preparation for treating acute leukemia and preparation method |
| CN107007722A (en) * | 2017-03-31 | 2017-08-04 | 天津市善济宏兴科技发展有限公司 | For treating the leukemogenic compound Chinese medicinal preparation of interior hot stasis institute and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101259235B (en) | 2011-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101229267A (en) | Medicine compounds for pulmonary and rheumatic heart disease and preparing method thereof | |
| CN101259235B (en) | Compound traditional Chinese medicine preparation for treating acute myeloblastic leukemia and producing method thereof | |
| CN101623352A (en) | Medicine for treating acne and preparation method thereof | |
| CN100542581C (en) | A kind of medicine for the treatment of chronic migraine and general headache | |
| CN103908543A (en) | Traditional Chinese medicine for treating sequelae of apoplexy and preparation method thereof | |
| CN101129512A (en) | Zegui oral liquid | |
| CN1337246A (en) | Chinese medicine for treating cerebral thrombus sequelae | |
| CN103006997A (en) | Medicine for treating post-craniotomy headache | |
| CN1408384A (en) | Pure traditional Chinese medicine preparation for curing lung cancer | |
| CN1073103A (en) | The prescription of curing thrombus capsule and preparation technology | |
| CN1589839A (en) | Stasis transforming pain relieving particle agent and its preparation method | |
| CN1322558A (en) | Liver cancer resisting medicine | |
| CN102743661B (en) | A kind of antipsoriatics thing and preparation method thereof | |
| CN103006995B (en) | Medicine for treating post-dural puncture headache (PDPHA) | |
| CN103330839B (en) | Traditional Chinese medicine for treating chronic gastritis | |
| CN108014222A (en) | Treat medicinal liquor of rheumatism and preparation method thereof | |
| CN1113804A (en) | Antianemic powder and its preparing method | |
| CN101396454B (en) | Traditional Chinese medicine for treating diabetic skin pruritus | |
| CN101810683B (en) | Chinese medicinal compound preparation for curing migraine and preparation process thereof | |
| CN101085185A (en) | Beverage containing white peony root and gardenia | |
| CN1730037A (en) | Process for preparing thrombus eliminating dripping pills | |
| CN1127968C (en) | Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method | |
| CN101129571A (en) | Oral liquid of prunella spike | |
| CN105031181A (en) | Medicinal liquor for treating rheumatic arthralgia and preparation method thereof | |
| CN1141109C (en) | Chinese patent medicine for curing acute leukemia and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110126 Termination date: 20140325 |